China Universal Asset Management Company’s Esperion Therapeutics ESPR Stock Holding History

China Universal Asset Management Company’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$129K	Sell	40,970 -1,454	-3%	-$4.07K	0.01%	394
2026 Q1	$116K	Buy	42,424 +3,469	+9%	+$11K	0.01%	395
2025 Q4	$144K	Buy	38,955 +3,614	+10%	+$11.7K	0.01%	380
2025 Q3	$93.7K	Sell	35,341 -4,467	-11%	-$8.64K	0.01%	391
2025 Q2	$39.2K	Buy	39,808 +286	+0.7%	+$286	﹤0.01%	432
2025 Q1	$56.9K	Sell	39,522 -2,257	-5%	-$4.16K	0.01%	411
2024 Q4	$91.9K	Buy	+41,779	New	+$97.5K	0.01%	403
2023 Q4	–	Sell	-2,748	Closed	-$2.69K	–	445
2023 Q3	$2.69K	Buy	2,748 +1,507	+121%	+$2.18K	﹤0.01%	421
2023 Q2	$1.73K	Buy	1,241 +203	+20%	+$283	﹤0.01%	435
2023 Q1	$1.65K	Buy	1,038 +289	+39%	+$1.49K	﹤0.01%	438
2022 Q4	$4.67K	Buy	749 +126	+20%	+$901	﹤0.01%	307
2022 Q3	$4K	Buy	+623	New	+$4.28K	﹤0.01%	295

Other funds holding ESPR

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

China Universal Asset Management Company's ESPR Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Esperion Therapeutics (ESPR) stake by 3.4% in Q2 2026, selling an estimated $4.07K and leaving 40,970 shares worth $129K. The position accounts for 0.01% of the portfolio, ranked #394.

China Universal Asset Management Company first reported a position in ESPR in Q3 2022 and has held it in 12 quarters since. The position peaked at $144K in Q4 2025. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

China Universal Asset Management Company held 40,970 shares of Esperion Therapeutics worth $129K as of Q2 2026.
China Universal Asset Management Company sold 1,454 Esperion Therapeutics shares in Q2 2026, an estimated $4.07K.
Esperion Therapeutics made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #394 holding.
China Universal Asset Management Company first reported a position in Esperion Therapeutics in Q3 2022 and has held it in 12 quarters since.
China Universal Asset Management Company's Esperion Therapeutics position peaked at $144K in Q4 2025.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.